ArticleNeuro-oncology advances

Evaluating hematologic parameters in newly diagnosed and recurrent glioblastoma: Prognostic utility and clinical trial implications of myelosuppression.

Davy Deng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.